Vascular endothelial growth factor inhibitors in colon cancer
- PMID: 17163170
- DOI: 10.1007/978-1-4020-5133-3_20
Vascular endothelial growth factor inhibitors in colon cancer
Abstract
Angiogenesis, the process by which new blood vessels are formed from preexisting vessels, is essential for growth and progression of solid tumors. A number of growth factors regulate angiogenesis, but vascular endothelial growth factor (VEGF) is the most important. Activation of the VEGF pathway triggers a range of signaling processes, stimulating vascular endothelial cell growth, migration, survival, and permeability. VEGF is expressed by most human cancers and its expression often correlates with tumor progression and poor prognosis. In contrast, VEGF plays a limited role in adult physiological angiogenesis, making it an ideal target for therapeutic agents designed to inhibit tumor angiogenesis. Disruption of VEGF signaling can occur through inhibition of the VEGF ligand or receptors, and preclinical models have shown that VEGF and VEGF receptors are viable targets for antiangiogenic agents.
Similar articles
-
Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.Semin Oncol. 2002 Dec;29(6 Suppl 16):3-9. doi: 10.1053/sonc.2002.37265. Semin Oncol. 2002. PMID: 12516032 Review.
-
Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.Semin Oncol. 2002 Dec;29(6 Suppl 16):10-4. doi: 10.1053/sonc.2002.37264. Semin Oncol. 2002. PMID: 12516033 Review.
-
Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.Int J Cancer. 2014 Jul 15;135(2):295-307. doi: 10.1002/ijc.28686. Epub 2014 Jan 6. Int J Cancer. 2014. PMID: 24375080
-
Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.Br J Cancer. 2016 Sep 6;115(6):691-702. doi: 10.1038/bjc.2016.236. Epub 2016 Aug 16. Br J Cancer. 2016. PMID: 27529514 Free PMC article.
-
Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.Curr Med Chem. 2006;13(16):1845-57. doi: 10.2174/092986706777585059. Curr Med Chem. 2006. PMID: 16842197 Review.
Cited by
-
Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.World J Gastroenterol. 2007 Dec 14;13(46):6231-5. doi: 10.3748/wjg.v13.i46.6231. World J Gastroenterol. 2007. PMID: 18069765 Free PMC article. Clinical Trial.
-
An update in the use of antibodies to treat glioblastoma multiforme.Autoimmune Dis. 2013;2013:716813. doi: 10.1155/2013/716813. Epub 2013 Nov 5. Autoimmune Dis. 2013. PMID: 24294521 Free PMC article. Review.
-
Colon cancer stem cells: implications for prevention and therapy.Trends Mol Med. 2008 Nov;14(11):503-9. doi: 10.1016/j.molmed.2008.09.005. Epub 2008 Oct 17. Trends Mol Med. 2008. PMID: 18929507 Free PMC article. Review.
-
In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model.Invest Radiol. 2009 May;44(5):265-70. doi: 10.1097/RLI.0b013e31819f1b60. Invest Radiol. 2009. PMID: 19346961 Free PMC article.
-
Bevacizumab: a review of its use in metastatic colorectal cancer.Drugs. 2008;68(4):487-506. doi: 10.2165/00003495-200868040-00009. Drugs. 2008. PMID: 18318567 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources